Lisinopril

Lisinopril Impurities

Lisinopril impurities include synthetic intermediates, process-related compounds, and degradation products that may arise during manufacturing, formulation, or storage. As an ACE inhibitor used to treat hypertension and heart failure, impurity profiling is essential to ensure product safety, therapeutic efficacy, and regulatory compliance. All impurity compounds are structurally characterized and qualified under ICH guidelines for toxicological evaluation and analytical validation.

Lisinopril EP Impurities

We offer pharmacopeial and non-pharmacopeial Lisinopril impurity compounds that conform to European Pharmacopoeia (EP) specifications. These standards support method development, impurity profiling, and stability studies. EP traceable compounds are available upon request and are supplied with validated analytical data including HPLC purity, NMR, and MS characterization.

Lisinopril Related Compounds

Our catalog includes structurally related compounds and synthetic intermediates associated with Lisinopril. These compounds are used in forced degradation studies, impurity identification, and toxicological qualification. Related substances may include diketopiperazine derivatives, stereoisomeric variants, and lysine analogs. All entries are supported by comprehensive analytical documentation and meet international regulatory expectations.

Lisinopril Impurity Reference Standards

Lisinopril impurity reference standards are supplied with validated analytical data including NMR, MS, and HPLC purity. These compounds are used in pharmaceutical R&D, method validation, and GMP-compliant quality control. EP/USP traceable entries are available upon request. All products are re-tested at regular intervals to ensure consistency and reliability.